Antimicrobial activity of the toxin VdTX-I from the spider *Vitalius dubius* (Araneae, Theraphosidae)

Rafael Sutti a, Bruno Bezerra Rosa a, Bettina Wunderlich b, Pedro Ismael da Silva Junior c, Thomaz Augusto Alves da Rocha e Silva a, *

a Departamento de Ciências Fisiológicas-Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brasil
b Johns Hopkins University, Baltimore, MD, USA
c LETA-Laboratório Especial de Toxinologia Aplicada – Instituto Butantan, São Paulo, Brasil

**Abstract**

Background: Currently there is an urgent need to develop new classes of antimicrobial agents with different mechanisms of action from conventionally antibiotics used for the control of pathogenic microorganisms. The acylpolyamine called VdTX-I was isolated from the venom of the tarantula *Vitalius dubius*, and first described with activity as an antagonist of nicotinic cholinergic receptors. The main objective of this study was to investigate the antimicrobial activity found in the venom of the spider, with emphasis on the toxin VdTX-I.

Methods: Antimicrobial assays were performed in 96 well plates culture against 14 micro-organisms (fungi, yeasts and bacteria), which were tested concentrations from 0.19 to 100 μM of VdTX-I. After qualitative analysis, dose-response curve assays were performed in bacterial kill curve using MTT reagent and hemolytic assay.

Results: The antimicrobial activity of the VdTX-I toxin was observed in 12 tested species of *Candida, Trichosporium, Staphylococcus* and *Micrococcus*. The toxicity had a dose-response at 3.12 μM – 100 μM in *Candida albicans, Candida guillermondii, Micrococcus luteus* and *Escherichia coli*. VdTX-I took about 5 min to inhibit bacterial growth, which was faster than streptomycin. The toxin showed no hemolytic activity between 0.19 and 100 μM. At 2.5 μg/mL of toxin it was observed no growth inhibition against a mammalian cell lineage.

Conclusions: The VdTX-I toxin has a significant antimicrobial activity, with broad spectrum, and is experimentally inert to mammalian blood cells.

General Significance: This paper explores the antimicrobial potential of the spider toxin VdTX-I, which can provide a new model to design new antimicrobial drugs.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The introduction of antibiotics was largely responsible for the dramatic decline in the mortality rate of diseases reported in developed countries. However bacteria are remarkably adaptable to environmental stresses and have evolved at least one mechanism of resistance for all 17 classes of antibiotics developed to date [1].

Many in use active molecules were obtained from organisms. One of the findings are the biogenic amines (polyamines, acylpolyamines), which are particularly powerful and have a wide spectrum of action. Typically its activity is not restricted to a single type of pathogen as Gram-positive and Gram-negative bacteria, fungi, protozoa [2].

Polyamines are found in nearly all living organisms and cell-sand can be well studied as putrescine, spermidine and spermine. It contains polycations that can interact with polyanionic macromolecules such as DNA, RNA, ion channels and protein kinases. This interaction promotes the regulation of gene expression, post-translational modifications, and alterations in the cell cycle, cell membrane structure and function. Thus, the polyamines also play an important role in the regulation of growth, development and function of animals, plants and microorganisms. In addition, the concentration and composition may present a great variation according to the cell type and the physiological conditions of the organism [3].

Further present in many organisms, the polyamines can have several applications such neuroprotective effect in animal models of multiple sclerosis [4], antimalarial and antitripansosomal activity [5,6] and have high efficiency and low toxicity against Chagas disease [7]. Synthetic polyamines can act as antimicrobial agents that...
may interact with the membrane of microorganisms, resulting in their breakage. It can also be covalently attached to the surface of medical implants, surfaces of medical materials, in order to prevent adhesion or growth of microorganisms [8].

In the venom of spiders, identification of antimicrobial compounds is constant, as in the case of Cupiennius salei [9,10], and Ornithoctonus hainana [11]. The antibiotic property is presumed to avoid infection by bacteria, fungi and yeasts on feeding, since these animals carry out extracorporeal digestion [11]. Nevertheless, all cited molecules are peptides.

Spider venoms are known as sources of many natural products, particularly acylpolyamines. Have been characterized in the venom of spiders mygalomorph such as putrescine, cadaverine, spermidine and spermine were characterized in the venom of spiders mygalomorph Scorda grisepes, Atrax robustus, and species of tarantulas spiders Dugesiella hentzi, Aphonopelma emilia and two other species Aphonopelma [15,16].

Among species of São Paulo state, the venom of tarantula Vitalius dubius, a variety of peaks seen in reversed phase chromatography and the range of molecular masses observed after SDS-PAGE and immunoblotting indicated that the venom of this spider contained several components, especially low molecular weight indicating a large amount of peptides, [17] Rocha-e-Silva et al. purified the polypeptide VdTX-I, arising from tarantula spider V. dubius, and showed that this toxin was capable of producing reversible blockade in biventer cervices neuromuscular preparations. [18]

In this context, this paper proposes to evaluate the antimicrobial activity of the toxin VdTX-I.

2. Materials and methods

2.1. Spiders

The spiders were obtained at Centro de Animais Peçinhentos René D’ávila, Itu, Brasil. After identification, the animals were brought to the Butantan Institute, where they were kept in a variarium of Silva Jr’s Laboratory. The venoms of spiders are extracted by electro stimulation, as described by Rocha-e-Silva [17].

2.2. Fractionation and purification

The venom of V. dubius and VdTX-I were obtained following the method proposed by Rocha-e-Silva [18] protocol.

2.3. Antimicrobial activity

For antimicrobial activity test the bacterial growth in liquid medium assay was used [19]. In a 96-well micro plate, 10 μL of the toxin or water (control) were applied to wells of 90 μL of the culture medium PB (Poor Broth) used for bacteria and PDB (Potato Dextrose Broth) used for fungi and yeasts in the logarithmic phase of growth. The absorbance of the cultures was measured after 18 h incubation at 30 °C on a micro plate reader EIA/plate reader (LABSYSTEM™) and Victor3 (1420 Multilabel Counter/Victor3 – Perkin Elmer) at 595 nm.

The VdTX-I toxin was tested against 15 microorganisms at concentrations from 0.19 to 100 μM (Aspergillus niger, Cladosporium sp., Trichosporum sp. IOC4569, Micrococcus luteus A270, Staphylococcus aureus ATCC29213, Staphylococcus epidermidis ATCC12223, Enterobacter cloacae B12, Escherichia coli ATCC 25922, E. coli D31, Candida albicans MDM8, Candida parapsilosis IOC4564, Candida guillermondii IOC4557, Candida tropicalis IOC4565, Candida glabata IOC4566 and Candida krusei IOC4559). Furthermore, quantitative analysis (dose-response) was performed and the dose-response curve was performed using 4 microorganism (C. albicans MDM8, C. guillermondii IOC4557, M. luteus A270 and E. coli ATCC 25922).

Since it is a qualitative test, the Minimum Inhibitory Concentration (MIC) is between the highest value without activity and the lowest active concentration, and thereby presented as a narrow range of concentrations.

2.4. Kill curve assay

To evaluate the minimum time that VdTX-I toxin acts on microorganisms, the kill curve assay was performed according to the protocol described by Wang [20] with modifications.

For this assay, 50 μM toxin were added 200 μL of suspension of E. coli D31 and M. luteus A270 at a concentration of 10⁶ CFU and were incubated at 37 °C at times 0, 5, 10, 15, 30, 60, 120, 180 and 240 min. After incubation were added 20 μL of a solution at 5 mg/mL of 3-(4,5-imethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and incubated at 37 °C for 20 min. Then, the tubes were centrifuged at 10,000 g for 30 s and the supernatant was removed leaving the formazan crystals at the bottom of the tubes. The crystals were dissolved in 1 mL of isopropanol and this volume was transferred to glass tubes, and further added 1.5 mL of isopropanol to obtain a final volume of 2.5 mL. Reading was performed in 96-well plates at 595 nm. As a positive control the same procedure was performed with 20 μL of antibiotic Streptomycin instead toxin, and as negative control 20 μL of ultra-pure H₂O was used.

2.5. Hemolytic activity

In this evaluation, human erythrocytes were collected in 0.15 M citrate buffer pH 7.4 and washed 3 times by centrifugation at 700g with PBS pH 7.4. After the last centrifugation the cells were resuspended in PBS pH 7.4. Aliquots at a concentration of 0.19 to 100 μM VdTX-I were added to the 96 well plate with bottom “U”, where in each well containing 50 μL of a suspension of erythrocytes to 3%. After that, the samples were incubated at room temperature for 3 h. Hemolysis was determined by reading absorbance at 595 nm of each well in a bed of plates (Titertek Miltiskan Elfa B, Finland). As a positive control was used Triton, and as negative control was used PBS only.

**Table 1**

Minimum Inhibitory Concentration (MIC) of the toxin VdTX-I.

| Microorganism                  | MIC    |
|--------------------------------|--------|
| Aspergillus niger (isolate)    | ND     |
| Cladosporium sp. (isolate)     | 6.25–12.5 μM |
| Trichosporum sp. IOC4569       | 6.25–12.5 μM |
| Micrococcus luteus A270        | 6.25–12.5 μM |
| Staphylococcus aureus ATCC29213| 6.25–12.5 μM |
| Staphylococcus epidermidis ATCC12223 | 6.25–12.5 μM |
| Enterobacter cloacae B12       | 50 μM  |
| Escherichia coli ATCC 25922    | 6.25–12.5 μM |
| E. coli D31                    | 6.25–12.5 μM |
| Candida albicans MDM8          | 6.25–12.5 μM |
| Candida parapsilosis IOC4564  | ND     |
| Candida guillermondii IOC4557 | 6.25–12.5 μM |
| Candida tropicalis IOC4560     | 6.25–12.5 μM |
| Candida glabata IOC4565        | 6.25–12.5 μM |
| Candida krusei IOC4559         | 6.25–12.5 μM |

ND—Not Detected in test concentration.
2.6. Cytotoxic activity

The cytotoxicity assay was performed in K562 cells (human erythroleukemia) grown in RPMI-1640 culture medium supplemented with 10% fetal bovine serum, and 1% of solution antibiotic-antimicotic made with 10,000 U of penicillin, 10 mg of streptomycin, and 25 μg of amphotericin B, in an incubator at 37 °C with 5% CO₂. The number of K562 cells in the culture was set to 2 × 10⁶ viable with 96% in three bottles (12.5 cm²). Two concentrations of VdTX-I (2.5 μg/ml and 20 μg/ml) and the controls were applied. The counting was performed by hemocytometer method by exclusion of trypan blue and the cytotoxic potential, defined based on the control curve at time 24 and 48 h [21].

2.7. Statistical analysis

The results were expressed as mean ± error of mean (SEM), and statistical comparisons were made using analysis of variance (ANOVA) by Tukey test or Student t test to compare means. A value of p < 0.05 indicated significance.
The toxin VdTX-I showed activity against 13 microorganisms tested, mostly in the concentration of 12.5 to 100 μM (Table 1). Against the bacterium *E. cloacae* β12 the toxin showed activity at 50 μM. VdTX-I was not active against two microorganisms tested, *Candida parapsilosis* and *Aspergillus niger*.

A similar activity was observed when the toxin was tested in dose-response curve against *C. albicans* MDM8, *C. guilliermondii* IOC4557, *M. luteus* A270 and *E. coli* ATCC 25922. It was observed an inhibition of the growth of these microorganisms at concentrations of 3.12 μM, reaching full growth inhibition at 100 μM of toxin. (Fig. 1)

The incubation time that VdTX-I needed to act on microorganisms was determined by killing curve protocol against *M. luteus* (gran positive) and *E. coli* D31 (gran negative). Our results have shown that the toxin inhibits the growth of the bacteria *M. luteus* after 5 min of exposure and *E. coli* D31 has its growth inhibited after 10 min exposure. For comparison, streptomycin takes approximately 6% of hemolysis only at the highest concentration. (Fig. 2)

The hemolysis test showed that VdTX-I was not able to cause significant hemolysis at concentrations from 0.19 to 100 μM, with approximately 6% of hemolysis only at the highest concentration. (Fig. 3)

The cytotoxic activity of VdTX-I was tested using the concentrations of 2.5 and 20 μg/mL, and only in the concentration of 20 μg/mL a low inhibitory activity has been found in K562 erythroleukemia cells. (Fig. 4)

### 3. Results

The toxin VdTX-I showed activity against 13 microorganisms tested, mostly in the concentration of 12.5 to 100 μM (Table 1). Against the bacterium *E. cloacae* β12 the toxin showed activity at 50 μM. VdTX-I was not active against two microorganisms tested, *Candida parapsilosis* and *Aspergillus niger*.

A similar activity was observed when the toxin was tested in dose-response curve against *C. albicans* MDM8, *C. guilliermondii* IOC4557, *M. luteus* A270 and *E. coli* ATCC 25922. It was observed an inhibition of the growth of these microorganisms at concentrations of 3.12 μM, reaching full growth inhibition at 100 μM of toxin. (Fig. 1)

The incubation time that VdTX-I needed to act on microorganisms was determined by killing curve protocol against *M. luteus* (gran positive) and *E. coli* D31 (gran negative). Our results have shown that the toxin inhibits the growth of the bacteria *M. luteus* after 5 min of exposure and *E. coli* D31 has its growth inhibited after 10 min exposure. For comparison, streptomycin takes approximately 6% of hemolysis only at the highest concentration. (Fig. 2)

The hemolysis test showed that VdTX-I was not able to cause significant hemolysis at concentrations from 0.19 to 100 μM, with approximately 6% of hemolysis only at the highest concentration. (Fig. 3)

The cytotoxic activity of VdTX-I was tested using the concentrations of 2.5 and 20 μg/mL, and only in the concentration of 20 μg/mL a low inhibitory activity has been found in K562 erythroleukemia cells. (Fig. 4)

### 4. Discussion

Since antibiotics were introduced into clinical practice, bacterial pathogens have developed resistance that might reduce their effectiveness. Moreover, with opportunistic pathogens innate resistance to antibiotics has become particularly problems arising in hospital environments [22]. Thus, the research of new molecules may provide an alternative for this scenario.

In general polyamines such as poly(ethyleneimines) (PEIs) show strong antimicrobial activity against Gram-Positive bacteria, *Staphylococcus aureus*, and Gram-Negative Bacteria, *E. coli*. However, higher concentrations were required to destroy *E. coli* compared to *S. aureus*[23].

This can be explained by differences in cell wall structure of Gram-positive and Gram-negative bacteria. Gram-Positive microorganisms such as *Staphylococcus aureus*, has a relatively thick wall, but porous, as Gram-Negative bacteria such as *E. coli*, have an outer membrane structure, forming a barrier to foreign molecules. [23]

The VdTX-I toxin has its antimicrobial activity at a relatively high MIC of 12.5 to 100 μM, but shows a wide-spectrum, being active against gran negative and positive bacteria, fungi and yeasts. Compared to antimicrobial peptides from other animal venoms, they used to present a low MIC but an activity against few microorganisms, such as the Cupinin 1 (purified venom *C. salei*) with MIC between 0.31 0.62 μM and active against four bacterial species [24]. Furthermore, the Latarcins (1, 2a, 3a, 3b, 4a and 5) purified from the venom of the spider *Lachesana tarabaevi* (Zodariidae) also have a MIC between 0.5 and 2.9 μM. In this same venom we can find two other Latarcins (6a and 7) having antimicrobial activity with MIC greater than 70 μM [25], showing a similar activity to VdTX-I. Mygalin, an acylpolyamine from the hemocytes of the spider *Acanthoscurria gomesiana*, was active only against *E. coli* (MIC 85 μM) [26].

Antimicrobial peptides can be found in other animal venoms, such as from Migainin-2 [24], derived from the venom of the skin of African frog *Xenopus laevis* having MIC larger than 60 μM. High activity antimicrobial peptides can also be found in the venoms of scorpions. For example, BmkB1 (*Mesobuthus mortensi*) with MIC between 16 and 90 μM, and IsCT (*Opisthacanthus madascarensis*) with MIC between 0.7 and 150 μM. *Tityus serrulatus* peptide that may be greater than 150 μM, which have high MIC but a broad spectrum of activity as VdTX-I, revealing that its activity is relatively low [27].

The time that VdTX-I inhibits the growth of the bacteria *E. coli* and *M. luteus* was 5 and 10 min, respectively, which reflects an effect relatively slow when compared with La47, peptide isolated from the venom of spider *Lachesana sp.*, which has its action after 2 min of incubation against *E. coli*. The purified peptide from the venom of the scorpion *Centruroides suffusus suffusus*, the Css54, has its activity soon after the start of incubation time [28].

The low hemolytic activity displayed by VdTX-I, with 6% of hemolysis with 100 μM toxin, is comparable to the one caused by the peptide O-defensin, with 7% hemolysis after incubation under 36 μM [11]. On the other hand, the toxin *LyeTx-I* (purified from the spider *Lycosa erythrognatha*) has a high hemolytic activity, with 40% hemolysis at 0.13 μM [29] and Css54 with approximately 65% at 20 μM [28].

We did not observe the cytotoxicity of VdTX-I against K562 cells at the tested concentrations of 2.5 μg/mL, but at the concentration of 20 μg/mL, were observed a small activity. This may be due to the fact that some polyamines such as polyhexamethylene biguanide (PHMB) did not affect eukaryotic cells.
Since these cells have neutral phospholipids in the composition of the membrane and polyamines have increased activity on phospholipids acids present in the membranes of microorganisms [23]. Just as PHMB, VdTX-I also has selective action, making their cytotoxicity and irritation potential smaller than other antiseptics [23].

5. Conclusions

We can conclude that VdTX-I toxin has a significant antimicrobial activity and broad spectrum. Also is a toxin that acts relatively fast against the tested bacteria. The VdTX-I toxin has low hemolytic activity but is not active against tumor cells of a particular lineage.

Conflicts of interest

The authors declare no conflicts of interest

Acknowledgment

The authors would like to thank CAPES, CNPq and FAPESP for financial support

References

[1] N.J. Saez, S. Senff, J.E. Jensen, S.Y. Er, V. Herzig, L.D. Rash, G.F. King, Spider-venom peptides as therapeutics. Toxins 2 (2010) 2851–2871.
[2] R.E. Hancock, K.L. Brown, N. Mookherjee, Host defense peptides from invertebrates: emerging antimicrobial strategies, Immunobiology 211 (2006) 315–322.
[3] Z. Dai, Z. Wu, J. Wang, X. Wang, S. Jia, F.W. Bazer, G. Wu, Analysis of polyamines in biological samples by HPLC involving pre-column derivatization with o-phthalaldehyde and N-acetyl-L-cysteine, Amino Acids 46 (2014) 1557–1564.
[4] B. Moreno, I. Lopez, B. Fernaández-Díez, M. Gottlieb, C. Matute, et al., Differential neuroprotective effects of 59-deoxy-59-methylthioadenosine, PLoS ONE 9 (3) (2014) e90671.
[5] J. Wang, M. Kaiser, B.R. Copp, Investigation of indolglyoxamine and indolacetamide analogues of polyamines as antimalarial and antitrypanosomal agents, Mar. Drugs 12 (2014) 3138–3160.
[6] SmitFI, NDADFI. Synthesis, in vitro antimalarial activity and cytotoxicity of novel 4-aminoquinolinyl-chalcone amides, Biosc. Med. Chem. 2014, 12: 1128–1138.
[7] F. Olmo, C. Rotger, I. Ramirez-Macias, L. Martinez, C. Marín, L. Carreras, K. Urbanova, M. Veja, G. Chavez-Lema, A. Sampedro, M.J. Rosales, M. Sánchez-Moreno, A. Costa, Synthesis and biological evaluation of n,n′-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against chagas disease, J. Med. Chem. 57 (2014) 987–999.
[8] D.D. Larivé, M. Kargar, A. Sahari, L. Russel, K.T. Gause, B. Behkam, W.A. Ducker, Antimicrobial surfaces using covalently bound polylysamine, Biomacromolecules 15 (2014) 169–175.
[9] S. Haebeli, L. Kuhn-Nentwig, J. Schaller, W. Nentwing, Characterization of antibacterial activity of peptides isolated from the venom of the spider Cupiennius salei (Araneae: Ctenidae), Toxicon 38 (1999) 373–380.
[10] L. Kuhn-Nentwig, T. Sheynis, S. Kolusheva, W. Nentwig, R. Jelinek, N-terminal aromatic residues closely impact the cytolytic activity of Cupiennin1a, a major spider venom peptide, Toxicon 73 (2013) 177–186.
[11] H. Zhao, Y. Kong, H. Wang, T. Yan, F. Feng, J. Bian, Y. Yang, H. Yub, A defense-like antimicrobial peptide from the venoms of spider, Orinchothous hainana, J. Pept. Sci. 17 (2011) 540–544.
[12] S. Chesnov, L. Bigler, M. Hesse, Detection and characterization of natural polyamines by high-performance liquid chromatography-atmospheric pressure chemical ionization (electrospray ionization) mass spectrometry, Eur. J. Mass Spectrom. 8 (2002) 1.
[13] T. Igasaki, T. Nakajima, Acylpolyamines: mass spectrometric analytical methods for araneidae spider acylpolyamines, J. Toxicon. Tox Rev. 19 (2000) 23.
[14] SchauerA., BenzH., FiedlerW.Guggisberg, A., Bienz, S., Hesse, M. Polyamine toxins from the venom of spiders and wasps, Alkaloids 45:1.
[15] C. Lange, C. Paris, M.L. Celerier, The components of the venom of a spider Scordra griseipes. Part 1. Analysis of low molecular weight products using gas chromatography/mass spectrometry, Rapid Commun. Mass Spectrom. 6 (1992) 289.
[16] C. Lange, C. Paris, M.L. Celerier, The components of the venom of a spider Scordra griseipes. Part 2. Structural information on biogenic amines using tandem mass spectrometry, Rapid Commun. Mass Spectrom. 6 (1992) 517.
[17] T.A.A. Rocha-e-Silva, R. Sulti, S. Hyslop, Milking and partial characterization of venom from the Brazilian spider Vulturus dubius (Theraphosidae), Toxicon 53 (2009) 153–161.
[18] T.A.A. Rocha-e-Silva, S. Rostelato-Ferreira, G.B. Leite, P.I. da Silva Jr, S. Hyslop, L. Rodrigues-Simioni, VdTX-I, a reversible nicotinic receptor antagonist isolated from venom of the spider Vulturus dubius (Theraphosidae), Toxicon 70 (2013) 135–141.
[19] P. Bulet, J.L. Dimarcq, C. Huetru, M. Langueux, M. Charlet, Y. Heg, A. Van Dorselaer, J. Hoffmann, A novel inductible antibacterial peptide of Drosophila carries an O-glycosylated substitution, J. Biol. Chem. 268 (1993) 14893–14897.
[20] H. Wang, H. Cheng, F. Wang, D. Wei, X. Wang, An improved 3-(4,5-di-methylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) reduction assay for evaluating the viability of Escherichia coli cells, J. Microb. Methods 82 (2010) 330–333.
[21] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55–63.
[22] A.J. Weaver Jr, J.B. Shepard, R.A. Wilkinson, R.L. Watkins, et al., Antibacterial Activity of THAM Trisphenylguanide against Methicillin-Resistant Staphylococcus aureus, PLoS ONE 9 (5) (2014) e97742.
[23] C. Wiegand, M. Bauer, U.C. Hipler, D. Fischer, Poly(ethyleneimines) in dermal application: biocompatibility and antimicrobial effects, Int. J. Pharm. 456 (2013) 165–174.
[24] L. Kuhn–Nentwig, J. Muller, J. Schaller, A. Valz, M. Dathe, W. Nentwig, Cupiennin 1, a new family of highly basic antimicrobial peptides in the venom of the spider Cupiennius salei (Ctenidae), J. Biol. Chem. 277 (2002) 11208–11216.
[25] S.A. Kozlov, A.A. Vassilevski, A.V. Feofanov, A.Y. Surovoy, D.V. Karpunin, E. Grishin, Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity, J. Biol. Chem. 281 (30) (2006) 20983–20992.
[26] L.S. Pereira, P.I. Silva Jr, M.T.M. Miranda, L.C. Almeida, H. Naoiki, K. Konno, S. Daffre, Structural and biological characterization of one antibacterial acylpolyamine isolated from the hemocytes of the spider Acanthocurria gorhami, Biochem, Biophys. Res. Commun. 352 (2007) 953–958.
[27] A. Almaaytah, Q. Albalas, Scorpion venom peptides with no disulfide bridges: A review, Peptides 51 (2014) 35–45.
[28] E. Garcia, E. Villegas, G.P. Espino-Solis, A. Rodriguez, J.F. Paniagua-Solis, G. Sandoval-Lopez, L.D. Porsani, C. Corzo, Antimicrobial peptides from arachnid venoms and their microbical activity in the presence of commercial antibiotics, J. Antimi. 66 (2013) 3–10.
[29] D.M. Santos, R.M. Verly, D. Piló-Veloso, M. de Maria, M.A.R. de Carvalho, D. S. Csalapin, B.M. Soares, C.G. Diniz, L.M. Farias, D.F.F. Moreira, F. Frézard, M. P. Benguerer, A.M.C. Pimenta, M.E. de Lima, LyteX-I, a potent antimicrobial peptide from the venom of the spider Lycosa erythronegata, Amino Acids 39 (2010) 135–144.